Navigation Links
Questcor to Report First Quarter Results on April 30, 2013
Date:4/15/2013

ANAHEIM, Calif., April 15, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced that it will release first quarter 2013 financial results on Tuesday, April 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, April 30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website, http://ir.questcor.com/
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 34200996.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Fourth Quarter and Full Year 2012 Results
2. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
3. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
4. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
6. Questcor to Conduct Conference Call to Discuss Reimbursement Process
7. Questcor Comments on Insurance Policy Bulletin
8. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
9. Questcor Pharmaceuticals to Present at Investor Conferences in September
10. Questcor Reports Second Quarter Financial Results
11. Questcor to Report Second Quarter Results on July 24, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... LOS GATOS, Calif. (PRWEB) , ... January 08, ... ... Poelstra, of The Robotic Spine Institute of Silicon Valley, has this week announced ... the West Coast using a Molybdenum-Rhenium rod in a patient. , The newly ...
(Date:1/8/2020)... PHOENIX (PRWEB) , ... January 09, 2020 , ... R3 ... for providers, including over 50 first rate presentations and procedure videos. The course is ... for one's malpractice carrier. , For years, R3 Stem Cell has been the leader ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... (BP) sensor system for integration in hearables and wearables. Valencell will provide the ... manufacturers for inclusion in their products. Embedded in an earbud reference design, the ...
Breaking Medicine Technology:
(Date:1/7/2020)... ... ... Destressing the patient payment and billing experience, balancing accelerating cash and reducing bad debt, ... examined at the HFMA Western Symposium, to be held January 12-15, 2019, at the ... in supporting hospitals to more effectively source and manage revenue cycle vendors, will moderate ...
(Date:1/7/2020)... ... January 07, 2020 , ... Iconic singer, choreographer and actress ... one of the most successful female artists of all time, but also for looking ... Vegas residency and shared in interviews her secrets to making it through 10 hour ...
(Date:1/7/2020)... , ... January 07, 2020 , ... ... Training Course , which includes comprehensive presentations and procedures for hair restoration, facial ... a completion certificate available. , Regenerative aesthetics has become incredibly popular over the ...
(Date:1/5/2020)... ... , ... Urban Air, the premier family-friendly indoor trampoline and entertainment center, wants ... hours of trampolining, rock climbing, dodge-balling and more, has announced the location of its ... “We know families are looking for ways to spend time together – and the ...
(Date:1/2/2020)... Calif. (PRWEB) , ... January 02, 2020 , ... NEA ... new Jeep® Compass* from California Casualty . , Educators lead extremely busy ... they are behind the wheel. From smartphones to navigation devices, new technology is a ...
Breaking Medicine News(10 mins):